Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to detection of HCV RNA in blood

Hepatology

Volumn 29, Issue 4, 1999, Pages 1288-1298

  Beld, Marcel ^a,d   Penning, Maarten ^a   Van Putten, Marieke ^a   Lukashov, Vladimir ^a   Van Den Hoek, Anneke ^b   Mcmorrow, Martin ^c   Goudsmit, Jaap ^a,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c Chiron Diagnostics   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; EPITOPE; NONSTRUCTURAL PROTEIN 3; PROTEIN NS4; PROTEIN NS5; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENIC VARIATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SEQUENCE HOMOLOGY; SEROCONVERSION; VIREMIA; VIRUS DETECTION;

EID: 0032901389     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290442     Document Type: Article

References (12)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injecting drug users. Medicine 1995;74:212-220.
3. van den Hoek JAR, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990;162:823-826.
4. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993;6:602-610.
5. Esteban R. Epidemiology of hepatitis C virus infection. J Hepatol 1993;17(Suppl 3):S67-S71.
6. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, Grigioni W, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
7. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990;87:6547-6549.
8. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. Sentinel county chronic non-A nh. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
9. Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, Sayade C, et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clin Microbiol 1996;34:80-83.
10. Dow BC, Buchanan I, Munro H, Follett EAC, Davidson F, Prescott LE, Yap PL, et al. Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors. J Med Virol 1996;49:132-136.
11. Dow BC, Munro H, Buchanan I, Follett EAC, Davidson F, Yap PL, Simmonds P. Third-generation recombinant immunoblot assay: comparison of reactivities according to hepatitis C virus genotype. Transfusion 1996;36:547-551.
12. Ragni MV, Ndimbie OK, Rice EO, Bontempo FA, Nedjar S. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion." Blood 1993;82:1010-1015.